Company Overview
Alnylam has led the translation of RNA interference into a new class of approved and investigational
medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system
(CNS)/ocular diseases. Learn more: www.alnylam.com.
Resources are intended for U.S. Healthcare Professionals only.
